ACUTAAS CHEMICALS LIMITED Stock Price Today (NSE: ACUTAAS)
Fundamental Score
ACUTAAS CHEMICALS LIMITED Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ACUTAAS CHEMICALS LIMITED share price today is ₹3037.60, up +0.62% on NSE/BSE as of 18 June 2026. ACUTAAS CHEMICALS LIMITED (ACUTAAS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.53K (Cr). The 52-week high for ACUTAAS share price is ₹3188.10 and the 52-week low is ₹1059.00. At a P/E ratio of 64.86x, ACUTAAS is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.00% and a debt-to-equity ratio of 0.01.
ACUTAAS CHEMICALS LIMITED Share Price Chart — NSE/BSE Historical Performance
ACUTAAS CHEMICALS LIMITED share price chart: 20.48% return over the past month. 52-week high ₹3188.10, 52-week low ₹1059.00.
ACUTAAS CHEMICALS LIMITED — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹3000.00 | ₹3059.80 | ₹2902.00 | ₹3037.60 | 4.30L (Cr) | |
| ₹3176.70 | ₹3188.10 | ₹2995.80 | ₹3018.90 | 3.06L (Cr) | |
| ₹3009.90 | ₹3184.90 | ₹2991.00 | ₹3132.50 | 6.02L (Cr) | |
| ₹3049.00 | ₹3075.30 | ₹2989.00 | ₹3000.60 | 2.07L (Cr) | |
| ₹2923.80 | ₹3069.00 | ₹2918.00 | ₹3034.80 | 5.31L (Cr) | |
| ₹2920.00 | ₹2963.30 | ₹2864.20 | ₹2923.80 | 3.34L (Cr) | |
| ₹2997.00 | ₹3001.00 | ₹2930.00 | ₹2951.20 | 3.34L (Cr) | |
| ₹2890.00 | ₹3025.00 | ₹2875.30 | ₹3000.40 | 8.25L (Cr) | |
| ₹2870.00 | ₹2909.80 | ₹2849.00 | ₹2880.60 | 3.89L (Cr) | |
| ₹2809.10 | ₹2906.00 | ₹2809.00 | ₹2886.50 | 6.08L (Cr) |
ACUTAAS CHEMICALS LIMITED — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹3176.70 | ₹3188.10 | ₹2902.00 | ₹3037.60 | -4.38% | |
| ₹2629.70 | ₹3184.90 | ₹2538.00 | ₹3132.50 | +19.12% | |
| ₹2626.00 | ₹2710.00 | ₹2073.00 | ₹2594.10 | -1.21% | |
| ₹2058.70 | ₹2580.00 | ₹2055.00 | ₹2558.60 | +24.28% | |
| ₹1818.00 | ₹2200.00 | ₹1817.00 | ₹2158.80 | +18.75% | |
| ₹1710.00 | ₹1968.00 | ₹1570.00 | ₹1912.50 | +11.84% | |
| ₹1847.20 | ₹1848.10 | ₹1613.20 | ₹1704.90 | -7.70% | |
| ₹1732.60 | ₹1902.00 | ₹1661.00 | ₹1837.50 | +6.05% | |
| ₹1302.00 | ₹1868.20 | ₹1302.00 | ₹1727.70 | +32.70% | |
| ₹1418.00 | ₹1530.30 | ₹1305.60 | ₹1317.80 | -7.07% | |
| ₹1351.90 | ₹1445.00 | ₹1261.20 | ₹1406.00 | +4.00% | |
| ₹1130.00 | ₹1350.00 | ₹1084.70 | ₹1327.40 | +17.47% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Acutaas is a high-growth specialty chemical play with aggressive diversification plans, but rich valuation and execution risks demand close monitoring.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Acutaas Chemicals launched its second 'Saksham Niveshak' campaign to help shareholders claim unclaimed dividends and update KYC. Q3 FY26 results were strong, with revenue up 43% YoY to Cr and PAT surging 133.7% YoY to Cr. Management upgraded revenue guidance to ~30% for FY26.
CORE STORY (THE REAL GAME)
Acutaas is transforming from a pharma intermediate player to a diversified specialty chemicals platform, targeting high-growth segments like battery and semiconductor chemicals, alongside its pharma CDMO business.
- Strong Q3 FY26 results
- Expansion into battery chemicals
- Acquisition of Indichem
- Successful commissioning of Indichem plant
- Ramp-up of battery chemical production
- New CDMO contracts
- Rich valuation (P/E 64.86x vs industry 31.77x)
- Negative Free Cash Flow
- Micro/SME cap - liquidity risk
FII decreased by 0.1%, DII increased by 0.21%.
Indian pharma sector benefiting from 'Make in India' push and government initiatives like PLI schemes.
No. Free Cash Flow 5Y: ₹-418.98 Cr
Acutaas aims to become a key player in specialty chemicals. Success hinges on the commissioning of Indichem and ramp-up of battery chemical production in the next 6-12 months.
Primary Thesis Risk
Failure to execute diversification strategy and integrate Indichem acquisition.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
ACUTAAS CHEMICALS LIMITED Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ACUTAAS CHEMICALS LIMITED Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ACUTAAS across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (16.00%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.92%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.91%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (93.52%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.10%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (33.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (41.40% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (120.69x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Institutional Confidence (FII+DII: 39.43%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 64.86x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-418.98 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
ACUTAAS CHEMICALS LIMITED vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare ACUTAAS CHEMICALS LIMITED with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
ACUTAAS CHEMICALS LIMITEDACUTAAS CHEMICA...Selected✓ ACUTAAS • 543349 | 64.1/100 | ₹3037.60₹3038 | ₹14525.86₹14525.86 | 64.86Average 64.9 Average | 16.00%Good 16.00% Good | 19.92%Good 19.92% Good | 0.01Excellent 0.0 Excellent | 41.40%Excellent 41.40% Excellent | 33.26%Excellent 33.26% Excellent | 0.08% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
ACUTAAS CHEMICALS LIMITED PE Ratio History
Historical price-to-earnings ratio for ACUTAAS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹9.90 | ₹1704.90 | 172.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
ACUTAAS CHEMICALS LIMITED Dividend History
Annual cash dividends paid by ACUTAAS — dividend yield 0.08%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹12.28 Cr |
| FY 2024 | ₹10.93 Cr |
| FY 2023 | ₹10.94 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
ACUTAAS CHEMICALS LIMITED Quarterly Performance
Latest quarterly metrics for ACUTAAS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
24.10%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
93.52%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
33.26%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
41.40%
Compounded annual net profit growth over 5 years
ACUTAAS CHEMICALS LIMITED Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ACUTAAS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
ACUTAAS CHEMICALS LIMITED Financial Statements
Annual income statement, balance sheet and cash flow for ACUTAAS CHEMICALS LIMITED (ACUTAAS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for ACUTAAS CHEMICALS LIMITED
About ACUTAAS (ACUTAAS CHEMICALS LIMITED)
ACUTAAS CHEMICALS LIMITED is a dynamic force in the pharmaceutical sector, dedicated to pioneering innovative solutions and driving advancements in healthcare. With a global vision... and a commitment to excellence, Acutaas focuses on the intricate realm of pharmaceutical intermediates, serving as a crucial bridge between research and the production of life-enhancing medications. The company's core strength lies in its state-of-the-art research and development infrastructure, enabling its team of expert scientists to develop cutting-edge intermediates with precision and efficiency. Acutaas takes pride in its ability to deliver high-quality products that meet the stringent requirements of the pharmaceutical industry, catering to the needs of both regulated and generic active pharmaceutical ingredients manufacturers worldwide. The company's extensive portfolio encompasses a diverse range of pharmaceutical intermediates carefully designed for critical therapeutic applications. Acutaas specializes in intermediates used in the synthesis of active pharmaceutical ingredients (APIs) that address a wide array of health challenges, including those related to viral infections, inflammation, mental health disorders, oncological diseases, neurological conditions, mood disorders, and blood clotting. The meticulous approach to quality control ensures that each intermediate meets the highest standards of purity, stability, and efficacy, thus facilitating the production of safe and effective medications. Acutaas is unwavering in its dedication to providing reliable and innovative solutions to its partners in the pharmaceutical industry. Beyond pharmaceuticals, ACUTAAS CHEMICALS LIMITED extends its expertise to specialty chemicals for diverse industries. The company's custom-designed specialty chemicals are used in cutting-edge battery technologies, enhancing the performance and longevity of energy storage solutions. They also formulate specialty chemicals for the personal care industry, providing unique ingredients for advanced cosmetic and skincare products. In the realm of agriculture, Acutaas develops specialized chemicals that improve crop yields and protect against pests. Moreover, Acutaas specialty chemicals enhance the durability, aesthetics, and performance of coatings, ensuring lasting protection and visual appeal. Committed to innovation, ACUTAAS CHEMICALS LIMITED strives to deliver comprehensive solutions that enhance performance across multiple sectors.
Company Details
Key Leadership
ACUTAAS Share Price: Frequently Asked Questions
What is the current share price of ACUTAAS CHEMICALS LIMITED?
ACUTAAS CHEMICALS LIMITED (ACUTAAS) trades at ₹3037.60 on NSE and BSE. Market cap ₹14.53K (Cr). Educational data only.
What is the P/E ratio of ACUTAAS CHEMICALS LIMITED?
ACUTAAS CHEMICALS LIMITED has a P/E of 64.86x vs industry average 31.77x.
What is the Bull Run score for ACUTAAS CHEMICALS LIMITED?
ACUTAAS CHEMICALS LIMITED has a Bull Run score of 64.1/100 based on 25+ financial parameters.
Does ACUTAAS CHEMICALS LIMITED pay dividends?
ACUTAAS CHEMICALS LIMITED has a dividend yield of 0.08%. Past dividends don't guarantee future payments.
What is the ROE of ACUTAAS CHEMICALS LIMITED?
ACUTAAS CHEMICALS LIMITED has ROE of 16.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of ACUTAAS CHEMICALS LIMITED?
ACUTAAS CHEMICALS LIMITED has debt-to-equity of 0.01.
Is ACUTAAS CHEMICALS LIMITED a good investment?
Bull Run gives ACUTAAS CHEMICALS LIMITED a score of 64.1/100. This is not investment advice — consult a SEBI-registered advisor.